Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 6Completed 3

Sponsor Class

OTHER 12INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × endostar protein × Clear all
NCT00912392 2014-09-03

Etoposide-Carboplatin Alone or With Endostar for Extensive Disease Small Cell Lung Cancer (ED-SCLC)

Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

Phase 2 Completed
138 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01327235 2014-08-01

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 2 Completed
336 enrolled
Thoracic

Pleural Effusion, Malignant

NCT01531790 2013-01-16

A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡